John Robert  Wilson net worth and biography

John Wilson Biography and Net Worth

Director of AlloVir
Mr. Wilson has over 30 years of experience in the design, development and manufacture of products for the field of biotechnology, including cell culture devices and bioreactors. Mr. Wilson has obtained over 50 related patents with numerous patents currently pending. He is the co-inventor of the G-Rex® platform, which has revolutionized T cell manufacturing practices with its simple, reliable and scalable cell production. Mr. Wilson is also the co-inventor of the CELLineTM product line. Prior to co-founding Wilson Wolf Manufacturing and ViraCyte, Mr. Wilson was a principal mechanical engineer at Cellex Biosciences (now The Cell Culture Company) where he contributed to the world’s first commercially available fully-automated hollow fiber bioreactor cell culture system. Mr. Wilson has a BA in Business Administration and a BA in Economics from Hamline University in Minnesota and a B.S. in Mechanical Engineering from the University of Minnesota.

What is John Robert Wilson's net worth?

The estimated net worth of John Robert Wilson is at least $75.73 million as of March 16th, 2021. Mr. Wilson owns 7,799,350 shares of AlloVir stock worth more than $75,731,689 as of February 10th. This net worth estimate does not reflect any other assets that Mr. Wilson may own. Learn More about John Robert Wilson's net worth.

How do I contact John Robert Wilson?

The corporate mailing address for Mr. Wilson and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at ir@allovir.com. Learn More on John Robert Wilson's contact information.

Has John Robert Wilson been buying or selling shares of AlloVir?

John Robert Wilson has not been actively trading shares of AlloVir over the course of the past ninety days. Most recently, John Robert Wilson sold 8,695 shares of the business's stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $720.82, for a transaction totalling $6,267,529.90. Learn More on John Robert Wilson's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 46 times. They sold a total of 4,971 shares worth more than $82,278.96. The most recent insider tranaction occured on January, 23rd when General Counsel Edward Miller sold 52 shares worth more than $494.00. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 1/23/2025.

John Robert Wilson Insider Trading History at AlloVir

See Full Table

John Robert Wilson Buying and Selling Activity at AlloVir

This chart shows John Robert Wilson's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

AlloVir Company Overview

AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.71
Low: $9.61
High: $10.16

50 Day Range

MA: $10.29
Low: $8.77
High: $12.22

2 Week Range

Now: $9.71
Low: $7.96
High: $24.15

Volume

20,504 shs

Average Volume

37,427 shs

Market Capitalization

$48.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65